Read about NIAID-supported research to develop a dual-purpose vaccine to protect humans and wildlife against Ebola and rabies.
Ebola and Marburg hemorrhagic fevers are acute viral diseases that often lead to severe illness and death in humans and other primates. The infections typically affect multiple organs in the body and are often accompanied by hemorrhage (bleeding). Once the virus has been transmitted from an animal host to a human, it can then spread through person-to-person contact.
Researchers in the NIAID Division of Intramural Research and at the Institute’s Vaccine Research Center as well as NIAID-supported scientists in external facilities are studying all aspects of Ebola and Marburg viruses, how they spread, and how they cause disease.
Investigators seek better ways to diagnose and treat Ebola and Marburg fevers, including promising work on vaccines.
Media Availability: NIH Scientists Identify Protective Role for Antibodies in Ebola Vaccine Study—Jan. 14, 2013
NIH-Supported Experimental Marburg Vaccine Prevents Disease Two Days after Infection—June 16, 2010
Experimental Vaccine Protects Monkeys from New Ebola Virus—May 20, 2010
NIAID Media Availability: Vaccine Given Post-Exposure Protects Monkeys Against Deadly Marburg Virus—April 26, 2006
News from NIAID-Supported Institutions
back to top
Last Updated January 14, 2013
Last Reviewed May 14, 2010